Integra Lifesciences Holdings Corp (IART) Director Sells $718,545.62 in Stock

Integra Lifesciences Holdings Corp (NASDAQ:IART) Director James M. Sullivan sold 15,658 shares of the stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $45.89, for a total value of $718,545.62. Following the transaction, the director now directly owns 70,154 shares in the company, valued at approximately $3,219,367.06. The transaction was disclosed in a filing with the SEC, which is available at this link.

Integra Lifesciences Holdings Corp (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, April 26th. The life sciences company reported $0.39 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by $0.01. Integra Lifesciences Holdings Corp had a net margin of 6.09% and a return on equity of 16.11%. The company had revenue of $258.60 million during the quarter, compared to analyst estimates of $254.19 million. During the same quarter in the prior year, the company posted $0.38 earnings per share. The firm’s revenue for the quarter was up 9.2% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: “Integra Lifesciences Holdings Corp (IART) Director Sells $718,545.62 in Stock” was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.themarketsdaily.com/2017/05/20/insider-selling-integra-lifesciences-holdings-corp-iart-director-sells-718545-62-in-stock-updated.html.

Hedge funds have recently made changes to their positions in the stock. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Integra Lifesciences Holdings Corp by 77.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,697 shares of the life sciences company’s stock valued at $100,000 after buying an additional 742 shares in the last quarter. LS Investment Advisors LLC increased its stake in shares of Integra Lifesciences Holdings Corp by 90.7% in the first quarter. LS Investment Advisors LLC now owns 2,412 shares of the life sciences company’s stock valued at $102,000 after buying an additional 1,147 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Integra Lifesciences Holdings Corp by 223.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock valued at $107,000 after buying an additional 1,751 shares in the last quarter. First Manhattan Co. bought a new stake in shares of Integra Lifesciences Holdings Corp during the first quarter valued at about $117,000. Finally, Acrospire Investment Management LLC increased its stake in shares of Integra Lifesciences Holdings Corp by 66.7% in the third quarter. Acrospire Investment Management LLC now owns 1,500 shares of the life sciences company’s stock valued at $124,000 after buying an additional 600 shares in the last quarter. Hedge funds and other institutional investors own 44.37% of the company’s stock.

A number of equities research analysts have commented on IART shares. Piper Jaffray Companies reiterated an “overweight” rating and issued a $47.00 price target on shares of Integra Lifesciences Holdings Corp in a research note on Wednesday, March 22nd. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Integra Lifesciences Holdings Corp in a report on Wednesday, March 22nd. Royal Bank of Canada reissued a “sector perform” rating and issued a $48.00 price objective (up from $46.00) on shares of Integra Lifesciences Holdings Corp in a report on Tuesday, May 2nd. Finally, Jefferies Group LLC increased their price objective on Integra Lifesciences Holdings Corp from $50.00 to $52.00 and gave the company a “buy” rating in a report on Friday, April 28th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $48.83.

Integra Lifesciences Holdings Corp Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

12 Month Chart for NASDAQ:IART

Receive News & Ratings for Integra Lifesciences Holdings Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences Holdings Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply